California State Teachers Retirement System Kronos Bio, Inc. Transaction History

California State Teachers Retirement System

$80.4 Billion
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$1.34 - $2.62 $1,495 - $2,923	-1,116 Reduced 6.87%	15,126 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $263 - $629	183 Added 1.14%	16,242 $26,000
Q3 2022 Nov 18, 2022	SELL	$3.35 - $5.55 $4,485 - $7,431	-1,339 Reduced 7.7%	16,059 $54,000
Q2 2022 Aug 15, 2022	SELL	$3.12 - $7.52 $42,310 - $101,978	-13,561 Reduced 43.8%	17,398 $63,000
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $26,423 - $60,866	-4,221 Reduced 12.0%	30,959 $224,000
Q4 2021 Feb 15, 2022	BUY	$11.35 - $21.18 $4,959 - $9,255	437 Added 1.26%	35,180 $478,000
Q3 2021 Nov 15, 2021	SELL	$18.17 - $24.7 $341,123 - $463,717	-18,774 Reduced 35.08%	34,743 $728,000
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $620,431 - $896,659	30,898 Added 136.6%	53,517 $1.28 Million
Q1 2021 May 18, 2021	BUY	$27.0 - $32.48 $14,013 - $16,857	519 Added 2.35%	22,619 $662,000
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $589,628 - $844,882	22,100 New	22,100 $660,000

Others Institutions Holding KRON

# of Institutions

Shares Held

20.7M

Call Options Held

31.4K

Put Options Held

Vida Ventures Advisors, LLC

2.77M
Shares

$2.6 Million
3.24% of portfolio
Vanguard Group Inc Valley Forge, PA

1.92M
Shares

$1.81 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.86M
Shares

$1.75 Million
0.0% of portfolio
Partners Capital Investment Group, LLP Boston, MA

1.67M
Shares

$1.57 Million
0.04% of portfolio
Alphabet Inc. Mountain View, CA

1.44M
Shares

$1.35 Million
0.11% of portfolio

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.4M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.

Account